Understanding CA125 Assay Performance Across Methodological Types: A Meta-Analytical Review

2.50
Hdl Handle:
http://hdl.handle.net/10755/157963
Type:
Presentation
Title:
Understanding CA125 Assay Performance Across Methodological Types: A Meta-Analytical Review
Abstract:
Understanding CA125 Assay Performance Across Methodological Types: A Meta-Analytical Review
Conference Sponsor:Western Institute of Nursing
Conference Year:2005
Author:McLemore, Monica, Ph.D, MPH, RN
P.I. Institution Name:University of California, San Francisco
Title:Assistant Clinical Professor
Contact Address:520 Frederick Street , #31, San Francsico, CA, 94117, United States
Co-Authors:Bradley Aouizerat
CA125 is a tumor-associated antigen used to monitor the progression and regression of epithelial ovarian cancer. A normal serum level of CA125 is < 35 miu/ml. There are 5 major types of assays that have been developed for CA125. Purpose: Serum assays report variable sensitivity and specificity depending on assay type, source of specimen, and histopathological tumor type. Given the epitope identified by the detection antibody in all commercial assays currently in use, denatured, native, truncated and elongated degradation fragments in sera are quantitated. Despite over 2000 published articles since 1981, no comprehensive meta-analysis has been conducted to evaluate the performance of this assay across patient populations and histopathological types. Methods: A meta-analytic review was conducted to answer the following questions: 1)How do the 5 CA125 assay types perform if sensitivity and specificity are the outcome measures, based on histopathological type? 2)What is the effect size (magnitude) of the relationships? 3)How precise are first-generation assays as compared to second-generation assays? Twenty studies were included in the analysis and effect sizes with confidence intervals were calculated to answer the study questions. Sub-analyses were conducted to understand any confounding of assay performance with serial versus single measurement of patients and between/across assay performance bias based on assay manufacturer. Results: The second generation ELISA assays performed most accurately and consistently across histopathological types and patient populations. Implications: Clinical implications include the use of ELISA assays over all others and the same type of assay should be used when serially monitoring patients for recurrence.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Western Institute of Nursing

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleUnderstanding CA125 Assay Performance Across Methodological Types: A Meta-Analytical Reviewen_GB
dc.identifier.urihttp://hdl.handle.net/10755/157963-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Understanding CA125 Assay Performance Across Methodological Types: A Meta-Analytical Review</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Western Institute of Nursing</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2005</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">McLemore, Monica, Ph.D, MPH, RN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of California, San Francisco</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Assistant Clinical Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">520 Frederick Street , #31, San Francsico, CA, 94117, United States</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">McLemoreMR@alumni.ucsf.edu</td></tr><tr class="item-co-authors"><td class="label">Co-Authors:</td><td class="value">Bradley Aouizerat</td></tr><tr><td colspan="2" class="item-abstract">CA125 is a tumor-associated antigen used to monitor the progression and regression of epithelial ovarian cancer. A normal serum level of CA125 is &lt; 35 miu/ml. There are 5 major types of assays that have been developed for CA125. Purpose: Serum assays report variable sensitivity and specificity depending on assay type, source of specimen, and histopathological tumor type. Given the epitope identified by the detection antibody in all commercial assays currently in use, denatured, native, truncated and elongated degradation fragments in sera are quantitated. Despite over 2000 published articles since 1981, no comprehensive meta-analysis has been conducted to evaluate the performance of this assay across patient populations and histopathological types. Methods: A meta-analytic review was conducted to answer the following questions: 1)How do the 5 CA125 assay types perform if sensitivity and specificity are the outcome measures, based on histopathological type? 2)What is the effect size (magnitude) of the relationships? 3)How precise are first-generation assays as compared to second-generation assays? Twenty studies were included in the analysis and effect sizes with confidence intervals were calculated to answer the study questions. Sub-analyses were conducted to understand any confounding of assay performance with serial versus single measurement of patients and between/across assay performance bias based on assay manufacturer. Results: The second generation ELISA assays performed most accurately and consistently across histopathological types and patient populations. Implications: Clinical implications include the use of ELISA assays over all others and the same type of assay should be used when serially monitoring patients for recurrence.</td></tr></table>en_GB
dc.date.available2011-10-26T20:22:30Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T20:22:30Z-
dc.description.sponsorshipWestern Institute of Nursingen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.